Clinical trials
Antibody-drug Conjugates clinical trials
Below are recruiting antibody-drug conjugates clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06597721RecruitingPhase 1
ADCE-T02 for advanced solid tumors
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
Rogers, ArkansasAges 18 years+ - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Phoenix, ArizonaAges 18 years+ - NCT04300556RecruitingPhase 1/Phase 2
Testing an antibody-drug for advanced certain cancers
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Tucson, ArizonaAges 18 years+ - NCT04983121RecruitingPhase 2
Neoadjuvant pyrotinib plus ARX788 for HER2-positive breast cancer
This Phase 2 trial studies whether combining pyrotinib with ARX788 given before surgery can work better and be safe in people with HER2-positive breast cancer. It’s designed for tumors that did not respond well enough to earlier trastuzumab and pertuzumab treatment.
Shenyang, LiaoningAges 18–75 - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
San Francisco, CaliforniaAges 18 years+ - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
Duarte, CaliforniaAges 18 years+ - NCT06774027Recruiting
Breast cancer antibody-drug conjugate treatment registry
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06796517Recruiting
Immunotherapy for relapsed or refractory lymphoma
This trial tests immunotherapy for people with certain types of lymphoma (diffuse large B cell, primary mediastinal, high grade, or Burkitt) that came back or didn't respond to previous treatment. It aims to see if a new immune-based approach can help.
SeoulAges 19–74 - NCT06797999RecruitingPhase 1/Phase 2
Study of ADCE-D01 for soft tissue sarcoma
This trial tests a new drug called ADCE-D01 for people with soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if it is safe and effective.
Aurora, ColoradoAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT06877416Recruiting
Optimizing sequential ADC therapy for HER2-low breast cancer
This trial is for people with HER2-low breast cancer who have already received two or more antibody-drug conjugates (ADCs) in a row. Researchers want to find the best order to use these targeted therapies to get the most benefit.
Guangzhou, GuangdongAges Any age - NCT06918912RecruitingPhase 2
Loncastuximab tesirine for lymphoma after CAR-T therapy
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
Alessandria, ALESSANDRIAAges 18–99 - NCT07051850Recruiting
Quality of life study for relapsed myeloma immunotherapy
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Seocho, SeoulAges 19 years+ - NCT07087860RecruitingPhase 2
Plasma exchange plus targeted therapy for advanced bladder cancer
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Rochester, MinnesotaAges 18 years+ - NCT07164950Recruiting
Compression stockings to prevent nerve damage from ADC therapy
This trial tests whether wearing compression stockings can help prevent nerve damage (peripheral neuropathy) caused by a type of chemotherapy called antibody-drug conjugate (ADC) in people with advanced cancers like bladder cancer. If you are starting treatment with an ADC and don't have existing nerve problems, you may be able to join.
ShanghaiAges 18–75 - NCT07268053RecruitingEarly Phase 1
B7-H3 drug for recurrent brain tumor or brain metastases
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Phoenix, ArizonaAges 18 years+ - NCT07309770RecruitingPhase 2
Trastuzumab Rezetecan for advanced solid tumors that have stopped responding to standard treatments
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07379268Recruiting
Anti-HER2 drug for advanced bladder cancer
This trial tests an antibody-drug conjugate that targets HER2 in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for patients whose cancer has not responded to or stopped responding to platinum-based chemotherapy.
Jinan, ShandongAges 18–80 - NCT07520760RecruitingPhase 2
Eribulin Plus Anlotinib for HER2-Negative Breast Cancer
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
GuangzhouAges 18 years+ - NCT07582887Recruiting
Genetic Testing to Predict Side Effects from Breast Cancer Antibody Drugs
This study examines how genetic differences affect how your body handles three newer breast cancer medications (Sacituzumab Govitecan, Trastuzumab Deruxtecan, or Datopotamab Deruxtecan). A blood test will check your UGT1A1 gene to help doctors predict which side effects you might experience and adjust your treatment accordingly.
Granada, GranadaAges 18 years+ - NCT07610616Recruiting
Testing ADC Drug Effectiveness Using Lung Cancer Lab Models
This research study tests how a lung cancer drug called Trastuzumab deruxtecan (T-DXd) works by growing your cancer cells in a lab dish and studying them with your immune cells. The goal is to better understand which patients might benefit most from this treatment.
Guangzhou, GuangdongAges 18–100 - NCT06625593RecruitingPhase 1
Study of BG-C137 for advanced solid tumors
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Antibody-drug Conjugates trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody-drug conjugates?
- Yes. Clin2 currently lists 22 recruiting antibody-drug conjugates studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody-drug conjugates trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody-drug conjugates trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.